ArticleBMC pulmonary medicine2018
A case of allergic bronchopulmonary aspergillosis successfully treated with mepolizumab.
Article in BMC pulmonary medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- Pooled it
- Innate airway immune response to fungal allergens.Frontiers in immunology · 2026Review
- Narrative review: mucus plugging in chronic obstructive lung diseases and bronchiectasis.European clinical respiratory journal · 2026Review
- A Case Report of Refractory Allergic Bronchopulmonary Aspergillosis: The Art of Selection, Discontinuation and Switching Biologics.Journal of inflammation research · 2026Article
- A 48-year-old male with allergic bronchopulmonary aspergillosis: a rare case report.Annals of medicine and surgery (2012) · 2025Article
- Article
- Rapid onset of effect of benralizumab in a severe eosinophilic and allergic asthma patient with allergic bronchopulmonary aspergillosis.Respirology case reports · 2023Article
- Real-world efficacy of anti-IL-5 treatment in patients with allergic bronchopulmonary aspergillosis.Scientific reports · 2023Article
- Clinical Manifestations of Human Exposure to Fungi.Journal of fungi (Basel, Switzerland) · 2023Review
- Severe Fungal Asthma: A Role for Biologics and Inhaled Antifungals.Journal of fungi (Basel, Switzerland) · 2023Article
- Mepolizumab in allergic bronchopulmonary aspergillosis complicated by infection.Respiratory medicine case reports · 2023Article
- The Role of Comorbidities in Difficult-to-Control Asthma in Adults and Children.The journal of allergy and clinical immunology. In practice · 2022Article
- Allergic Bronchopulmonary Aspergillosis with an Atypical Mass-Like Presentation.Case reports in pulmonology · 2022Article
- Mepolizumab and dupilumab as a replacement to systemic glucocorticoids for the treatment of Chronic Eosinophilic Pneumonia and Allergic Bronchopulmonary Aspergillosis - Case series, Almoosa specialist hospital.Respiratory medicine case reports · 2021Article
- Asthma Phenotypes as a Guide for Current and Future Biologic Therapies.Clinical reviews in allergy & immunology · 2020Review
- Mepolizumab as Possible Treatment for Allergic Bronchopulmonary Aspergillosis: A Review of Eight Cases.Cureus · 2020Review
- Differential response to biologics in a patient with severe asthma and ABPA: a role for dupilumab?Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2020Article
- Successful treatment with mepolizumab for allergic bronchopulmonary mycosis complicated with bilateral septic arthritis of the knee joints caused by Methicillin-resistantRespiratory medicine case reports · 2020Article
- Current Approach in the Diagnosis and Management of Allergic Bronchopulmonary Aspergillosis in Children With Cystic Fibrosis.Frontiers in pediatrics · 2020Review
- Treatment of allergic bronchopulmonary mycosis: Experience of 55 patients with 124 relapses-A descriptive study.Clinical case reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAllergic bronchopulmonary aspergillosis (ABPA) is an allergic pulmonary disease comprising a complex hypersensitivity reaction to Aspergillus fumigatus. Clinical features of ABPA are wheezing, mucoid impaction, and pulmonary infiltrates. Oral corticosteroids and anti-fungal agents are standard therapy for ABPA, but long-term use of systemic corticosteroids often causes serious side effects. CASE PRESENTATION: A 64-year-old woman was diagnosed with ABPA based on a history of bronchial asthma (from 40 years of age), elevated total IgE, the presence of serum precipitating antibodies and elevated specific IgE antibody to A. fumigatus, and pulmonary infiltration. Bronchoscopy showed eosinophilic mucoid impaction. Systemic corticosteroid therapy was initiated, and her symptoms disappeared. Peripheral eosinophilia and pulmonary infiltration recurred five months after cessation of corticosteroid treatment. Systemic corticosteroids were re-initiated and itraconazole was added as an anti-fungal agent. The patient was free of corticosteroids, aside from treatment with a short course of systemic corticosteroids for asthma exacerbation, and clinically stable with itraconazole and asthma treatments for 3 years. In 2017, she experienced significant deterioration. Laboratory examination revealed marked eosinophilia (3017/μL) and a chest computed tomography (CT) scan demonstrated pulmonary infiltration in the left upper lobe and mucoid impaction in both lower lobes. The patient was treated with high-dose inhaled corticosteroid/long-acting beta-agonist, a long-acting muscarinic antagonist, a leukotriene receptor antagonist, and theophylline; spirometry revealed a forced expiratory volume in 1 s (FEV
conclusionsTo our knowledge, this is the first case of ABPA to be treated with mepolizumab. Dramatic improvements were observed in symptoms, lung function, peripheral eosinophil counts, and chest images. Mepolizumab could serve as an alternative treatment with the potential to provide a systemic corticosteroid-sparing effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.